Follicular lymphoma (FL) is a lymphoma of B cells in follicular center. It is a common pathological subtype of lymphoma, and its incidence rate is only next to diffuse large B cell lymphoma (DLBCL). The initial remission rate is high, but the tumor generally recurrent, making it difficult to be completely cured. This study attempts to explore the efficacy and safety of rituximab monotherapy maintenance after BR, RCHOP, R2 regimen induction therapy in the treatment of follicular patients, and to find the best way to maximize survival benefit and reduce treatment toxicity for FL patients. The study can improve the quality of life, prolong the survival and avoid the transformation to invasive lymphoma in patients with follicular lymphoma.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
Treatment naive
Age ≥ 18 years
Indications for treatment confirmed
Must has measurable lesion in CT or PET-CT prior to treatment
Considered suitable for RCHOP, BR or R2 regimens
Informed consented
You may not be if
Transformed follicular lymphoma or 3B follicular lymphoma;
HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive
Central nervous system or meninges involved
Any drug contraindication in the treatment plan
Patients judged by other researchers to be unsuitable for inclusion in the study